LLY

997.3

-0.85%↓

JNJ

241.92

-1.04%↓

ABBV

227.18

-0.36%↓

NVS

155.4

-4.26%↓

AZN

193.33

-1.76%↓

LLY

997.3

-0.85%↓

JNJ

241.92

-1.04%↓

ABBV

227.18

-0.36%↓

NVS

155.4

-4.26%↓

AZN

193.33

-1.76%↓

LLY

997.3

-0.85%↓

JNJ

241.92

-1.04%↓

ABBV

227.18

-0.36%↓

NVS

155.4

-4.26%↓

AZN

193.33

-1.76%↓

LLY

997.3

-0.85%↓

JNJ

241.92

-1.04%↓

ABBV

227.18

-0.36%↓

NVS

155.4

-4.26%↓

AZN

193.33

-1.76%↓

LLY

997.3

-0.85%↓

JNJ

241.92

-1.04%↓

ABBV

227.18

-0.36%↓

NVS

155.4

-4.26%↓

AZN

193.33

-1.76%↓

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Abierto

SectorSalud

228.88 -5.21

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

227.14

Máximo

241.22

Métricas clave
By Trading Economics
Ingresos	28M -33M
Ventas	32M 245M
Margen de beneficio	-13.56
Empleados	1,189
EBITDA	68M 15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+22.26% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	1.2B 15B
Apertura anterior	234.09
Cierre anterior	228.88

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

264 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2026, 20:38 UTC

Ganancias

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Charlas de Mercado

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Ganancias

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Noticias de Eventos Importantes

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Ganancias

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Ganancias

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Ganancias

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Ganancias

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Ganancias

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Charlas de Mercado

Ganancias

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Ganancias

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Ganancias

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Ganancias

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Ganancias

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Ganancias

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

22.26% repunte

Estimación a 12 meses

Media 293.33 USD 22.26%

Máximo 342 USD

Mínimo 255 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

264 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.